ArticleHeliyon2024
Low KeV virtual monoenergetic images for detecting low dose iodine- or alternative Gd-based IV contrast agents.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Understanding Photon-Counting CT: Physics, Detector Technology, and Image Reconstructions.Sensors (Basel, Switzerland) · 2026Review
- Photon counting detector CT contrast agent-reduced transcatheter aortic valve reconstruction planning: a comparative study.European radiology · 2026Article
- Development and validation of a machine learning-based radiomics model using 45-keV virtual monoenergetic images for differentiating fat-poor angiomyolipoma from clear cell renal cell carcinoma.Translational andrology and urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The recent shortage of iodine-based intravenous contrast and its cost highlight the need for limiting dose and alterative agents. Purpose: To quantify radiodensity (Hounsfield Units, HU) improvement and potential iodine dose reduction with low keV imaging compared to conventional polyenergetic reconstructions on dual source (DSCT) and dual layer (DLCT) CT and to assess potential utility of non-iodine gadolinium-alternatives with low keV imaging. Materials and methods: This phantom study used dilutions of three commercially-available contrast agents scanned by DSCT and DLCT. Conventional polyenergetic and virtual monoenergetic images (VMI) were reconstructed of each of five dilutions at five keV levels. HU and signal-to-noise ratios were compared among iodine- and gadolinium-based contrast agents. Results: Iodine- and gadolinium-based contrast agent HU increased inversely to keV for the same dilution in both scanners. At the lowest keV setting (40 keV), iodine-based contrast agent HU in VMIs with DLCT and DSCT were approximately 300 % and 400 % of conventional, respectively. Gd-based contrast agent HU in VMIs at low keV were similar to or better than conventional iodine HU. Comparing the dual energy CTs, although HU from iodine and gadolinium-based contrast agents for conventional polyenergetic reconstructions was similar, HU in VMIs of DSCT were right shifted compared to DLCT by ∼10 keV lower. Conclusion: Depending on CT scanner type, 1/3 to 1/4 dose of iodinated contrast at 40 keV provides HU similar to full dose conventional acquisition, suggesting 1/3-1/4 dose may be adequate clinically at 40 keV. Depending on the Gd-based contrast and CT type, Gd-based contrast at 40 keV provides similar or greater HU compared to conventional acquisitions with iodinated contrast, suggesting Gd-based contrast at 40 keV may serve as an alternative to iodinated contrast. HU on VMI images is scanner dependent, suggesting scanner-dependent protocol optimization and potentially monoenergy HU calibration between scanners is needed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.